Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

bserved in the vaccine group (n=8,757) compared to 29 cases in the placebo group (n=8,774).

Impact of GARDASIL in women already infected with HPV types targeted by the vaccine

This study also assessed the efficacy of GARDASIL in a broader population, including those who had HPV 6-, 11-, 16- or 18-related infection or disease at study initiation. In this group, GARDASIL reduced the incidence of HPV 16- or 18- related VIN 2/3 or VaIN 2/3 by 71 percent; nine cases were observed in the vaccine group (n= 9,087); 31 cases were observed in the placebo group (n=9,087). In eight of the nine vaccine cases and two of the placebo cases, individuals were infected with HPV 16 or 18 prior to receiving the first dose. There were also five cases of VIN 2/3 or VaIN 2/3 in the placebo group that were associated with HPV type 6 and not associated with type 16 or 18. None were associated with HPV type 11.

In all three studies used in the analysis, the adverse events observed were similar to what has been previously reported. The most common treatment-related adverse event was injection-site pain.

Additional important information about GARDASIL

The health-care provider should inform the patient, parent or guardian that vaccination does not substitute for routine cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care.

Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN. GARDASIL has not been shown to protect against disease due to other HPV types.

In clinical studies for GARDASIL, vaccine-related adverse experiences that were observed at a frequency of at least 1.0 percent among recipients of GARDASIL and also greater than those observed among recipients of placebo, respectively, were pain (83.9 percent vs. 75.4 percent), swelling
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company ... (TAP),technology, today announced that clinical findings for three,different ... are to be,reported at the 43rd American Society ... June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract ...
... 2007 - GTx, Inc., (NASDAQ:,GTXI) announced today that ... clinical trial of Ostarine(TM) and from the ongoing ... for the treatment of multiple side effects of ... upcoming 2007,Annual Meeting of the American Society of ...
Cached Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today its financial ... gain of $151.8 million, or $1.19 per share, from Medarex,s,sale ... 2008, Medarex,s,net income for the quarter ended March 31, 2008, ... net income of $110.3 million, or $0.88,per share for the ...
... MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, ... over the previous eight,months regarding the formation of ... in these negotiations where final written terms have ... to the Company,s very first,product acquisition. It should ...
... 12 The American Veterinary,Medical Association (AVMA) has reinforced ... horses and other equines by approving a,new policy on ... by the AVMA Executive Board on April 12, 2008,states ... AVMA opposes the,use of double-deck trailers to transport equines. ...
... The Myanmar Relief Fund,( http://www.MyanmarReliefFund.org ) is a ... the know-how to get aid in and directly ... are treating the,injured, and a myriad of supplies ... is a coalition of private American and Myanmar,citizens ...
... G.,Komen Pittsburgh Race for the Cure(R) are as follows:, 1st Place ... 15:14 Female: Kelly Knickelbein, Pittsburgh, Pa., 19:19, ... Burnett, 16:02 Female: Anna Beck, Washington, Pa., ... Charlie Ban, Pittsburgh, Pa., 16:13 Female: Jessica ...
... Better Care,Better Regulation, WASHINGTON, May 11 ... ManorCare nursing homes in sixteen states,across the nation ... a call to,action from quality care advocates. The ... Managing Director David Rubenstein to demand better,care. In ...
Cached Medicine News:Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2Health News:AVMA Opposes Use of Double-Deck Trailers for Transporting Horses and Other Equines 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Advocates Make Mother's Day Push for Quality Care 2
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... and Increase Staff Protection With Medline's Sterile Suction ... Fr, 16 Fr and 18 Fr), ,Medline ... the U.S. We manufacture most of our suction ... exceeds our customers' expectations. We manufacture, supply and ...
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
Medicine Products: